Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
Cannabis Use Disorder
About this trial
This is an interventional treatment trial for Cannabis Use Disorder focused on measuring Repetitive Transcranial Magnetic Stimulation, Cannabis, Substance Use Disorder, Prefrontal Cortex, Insula, Neuroimaging
Eligibility Criteria
Inclusion Criteria: Must be deemed to have capacity to provide informed consent Age between 18 to 65 Diagnosis of cannabis use disorder according to the DSM-5 and the Structured Clinical Interview for DSM-5 (SCID for DSM-541) Report cannabis as the primary drug of concern, a frequent pattern of use (≥5 days per week), and a goal of reduction or abstinence of cannabis use CUDIT-R score ≥12 Marijuana Contemplation Ladder ≥7 Cannabis positive urine drug screen, with Narcochek baseline THC-COOH level of >150 ng/ml. On a stable regimen of their psychotropic medications for 14 days before enrolment. Exclusion Criteria: Pregnant or intending to be pregnant during the study Diagnosis of bipolar disorder, schizophrenia spectrum disorder, or other active concurrent psychiatric disorder that is too unstable and may preclude safe participation in the trial as deemed by the PI. Substance use disorder other than cannabis or nicotine, that is of moderate severity or greater, or is the primary substance of concern based on the SCID for DSM-5 Known active seizure disorder, significant head injury with an imaging verified lesion Unstable medical illness Presence of cardiac pacemaker, intracranial implant, or metal in the cranium Participants taking > 2 mg lorazepam (or a benzodiazepine at an equivalent dose) or taking any anticonvulsant medication during treatment.
Sites / Locations
- Centre for Addiction and Mental HealthRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
High-Frequency (HF)
Low-Frequency (LF)
10 Hz rTMS
1 Hz rTMS